Hansoh Pharma's Olatorepatide Phase III Trial Results Presented at EASD
Hansoh Pharma presented Phase III trial results for Olatorepatide, showing a 19.3% body weight reduction at 48 weeks. The drug is a dual selective GLP-1/GIP receptor agonist.
Hansoh Pharma presented the results of its Phase III clinical trial for Olatorepatide at the annual European Association for the Study of Diabetes (EASD) conference held in Milan from September 28 to October 2, 2026. The study demonstrated a significant body weight reduction of 19.3% among participants after 48 weeks of treatment.
Olatorepatide is a dual selective GLP-1 and GIP receptor agonist developed by Hansoh Pharma, aimed at improving the management of type 2 diabetes. This Phase III trial was designed to assess the efficacy and safety profile of the drug in a larger patient cohort.
The key findings highlight Olatorepatide's potential in weight management, a critical factor for many individuals with type 2 diabetes. The presentation also covered the drug's overall tolerability and safety data, with further details anticipated.
The EASD conference is a major global event for diabetes research and care. Hansoh Pharma's presentation provides new insights into the company's drug development pipeline and its potential impact on future diabetes treatment strategies.